Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exelixis Inc (NQ: EXEL ) 26.50 +0.20 (+0.76%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Exelixis Inc < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Recap: Exelixis Q4 Earnings February 06, 2024 Via Benzinga Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update February 06, 2024 From Exelixis, Inc. Via Business Wire Earnings Scheduled For February 6, 2024 February 06, 2024 Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. Via Benzinga Earnings Preview For Exelixis February 05, 2024 Via Benzinga In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. February 05, 2024 NASDAQ:EXEL, a growth stock which is not overvalued. Via Chartmill Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February February 01, 2024 From Exelixis, Inc. Via Business Wire Breaking Down Exelixis: 7 Analysts Share Their Views January 30, 2024 Via Benzinga NASDAQ:EXEL is showing good growth, while it is not too expensive. December 21, 2023 Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 6 Analysts Have This to Say About Exelixis December 13, 2023 Via Benzinga Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 January 25, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 January 23, 2024 From Exelixis, Inc. Via Business Wire Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study January 23, 2024 Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial. Via Benzinga NASDAQ:EXEL, a growth stock which is not overvalued. November 29, 2023 Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL. Via Chartmill Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma January 22, 2024 From Bristol Myers Squibb Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session January 22, 2024 Via Benzinga 3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 January 21, 2024 These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024. Via InvestorPlace European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets January 18, 2024 From Exelixis, Inc. Via Business Wire 3 Pharma Stocks Could Be the Pills Your Portfolio Needs January 18, 2024 These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. Via InvestorPlace Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review January 12, 2024 The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. Via Investor's Business Daily Topics ETFs Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell' January 12, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified Via Benzinga Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. January 11, 2024 Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced. Via Chartmill Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? January 08, 2024 Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an Via Benzinga Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes January 08, 2024 Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco. Via Investor's Business Daily Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 January 07, 2024 From Exelixis, Inc. Via Business Wire Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 January 02, 2024 From Exelixis, Inc. Via Business Wire Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 December 07, 2023 From Exelixis, Inc. Via Business Wire Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer December 04, 2023 From Exelixis, Inc. Via Business Wire Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma December 04, 2023 From Arcus Biosciences Via Business Wire Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment November 29, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 November 21, 2023 From Exelixis, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.